Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Management and board changes at Revotar

This article was originally published in Scrip

Executive Summary

Revotar Biopharmaceuticals (Germany) has appointed Ludwig Felber chief financial officer and member of the executive board, and elected Professor Dr Wolfgang Hartwig as supervisory board member. Revotar's CEO, Dr Martin Pöhlchen, has also been appointed to the additional role of president. Mr Felber is the co-founder and former managing director of investment bank Viscardi. Professor Hartwig is managing director of Pharma R&D Consulting and the former global head of pharmaceutical R&D at Bayer HealthCare's pharmaceutical division.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC002445

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel